Why Achillion Pharmaceuticals (ACHN) Stock Is Up Today (Update)

Update (4:10 p.m.): Updated with Monday market close information.

NEW YORK (TheStreet) -- Achillion Pharmaceuticals  (ACHN) surged Monday amid news that Merck  (MRK) would purchase biotechnology company Idenix Pharmaceuticals  (IDIX) for $3.85 billion as it tries to strengthen its position in the increasingly competitive hepatitis C sector.

Achillion could be the next acquisition target for larger companies. CNBC reported Johnson & Johnson  (JNJ) and Abbvie  (ABBV) were both interested in buying Idenix but Merck secured the purchase. Those companies, among others, could now turn their focus to Achillion, which has a pipeline of hepatitis C drugs.

Merck will pay $24.50 a share in cash for Idenix, more than triple the company's closing price of $7.23 on Friday.

Must Read: Achillion Pharma Might be Next Hep C Takeout Target

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

"Idenix has established a promising portfolio of hepatitis C candidates,'' said Dr. Roger Perlmutter, the president of Merck Research Laboratories, in a statement Monday. 

Achillion stock closed up 47.57%, or $1.37, to $4.25. More than 46.9 million shares changed hands, which eclipsed the average volume of 1,420,150.

For more on the Achillion story, read TheStreet's Adam Feuerstein's article here.

ACHN Price Chart

ACHN Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Dow Tumbles as Trump Ratchets Up China Trade Fight

Dow Tumbles as Trump Ratchets Up China Trade Fight

Netflix Shares Hit All-Time High as Market Flounders

Netflix Shares Hit All-Time High as Market Flounders

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy